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Abstract
Background: Although systematic reviews (SR) report that human papillomavirus (HPV) increases the risk of breast
cancer, there are still disputes regarding this association. In particular, it has been argued that the risk level differs
depending on nationality, type of tissue, subtype of HPV, and publication year. Considering that the searching year
of publication for the previous SRs was June 2013, a renewal meta-analysis needs to be conducted.
Methods: Using articles selected in the previous SRs, we compiled a list of references, cited articles, and related
articles from the PubMed and Scopus databases. Of these, only publications with data from case-control studies on
HPV DNA-positivity in tissues were chosen. Summary odds ratio (SOR) and 95 % confidence interval (CI) were
calculated through meta-analysis. Meta-regression analysis was performed for nationality, types of tissue, subtype of
HPV, and publication year.
Results: Twenty-two case-control studies were selected, and the total number of individuals in the case and
control group was 1897 and 948, respectively. According to the meta-analysis about the 22 publications, HPV
infection increased the risk of breast cancer (SOR = 4.02, 95 % CI: 2.42–6.68; I-squared = 44.7 %). Statistical
significance was not found in meta-regression performed on the four variables of nationality, type of tissue,
subtype of HPV, and publication year which some researchers think sources of heterogeneity.
Conclusions: The results of the present study supported the argument that HPV infection increases the risk
of breast cancer. Age-matched case-control studies are in need in the future.
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Background
Breast cancer is a primary cancer that has one of the
highest incidences in women worldwide [1,2]. Epidemio-
logically, breast cancer occurs at a younger age for
Asians compared to individuals from western countries
[3]. Similarly, the peak incidence of breast cancer among
Korean women occurs around 45–49 years old, which is
immediately before menopause, and decreases after this
age, forming a single-peak curve [4]. Because the shape
of this curve had been maintained for the last 20 years,
it was reported that there was no cohort effect in age-
period-cohort analysis [5]. Based on the epidemiological
characteristics mentioned above, dense breast and
human papillomavirus (HPV) were proposed as risk fac-
tors related to the development of breast cancer among
Korean women [6,7].
In particular, the HPV infection theory is significant in
the prevention of cancer because HPV vaccines are cur-
rently in use [8]. The association between HPV infection
and breast cancer was first proposed in 1992 [9], and
since then there was a report of HPV DNA being de-
tected in breast cancer tissues of Korean women [10].
And three meta-analyses [11–13] reported that HPV
DNA was detected in 23–30 % of breast cancer tissues
and the summary odds ratio (SOR) was 3.24–3.63 with
statistical significance.
Nevertheless, there are still disputes about the associ-
ation between HPV infection and the risk of breast can-
cer [14]. In particular, there is debate over the use of
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paraffin-embedded tissue (PET) to test for HPV DNA-
positivity because HPV DNA can be destroyed and be-
come contaminated during the treatment procedure,
meaning that PET will have more measurement errors
than fresh frozen tissue (FFT) [15]. Although Li et al.
[12] emphasized that HPV 33 was detected in all Asians,
it was suggested that these regional differences can be
attributed to differences in the testing method [15]. In
addition, Zhou et al. [13] stressed that the risk of HPV
infection was influenced by geographic region, HPV
DNA source, PCR primer used, and publication year.
However in the subgroup analysis, the confidence inter-
vals of SOR overlapped with one another. Therefore, it
is necessary to further examine whether these variables
indeed cause heterogeneity. Furthermore, taking into ac-
count that the final search period of the 3 SRs was June
2013 [11], the meta-analysis needs to be adapted by add-
itionally selecting literatures published up to September
2015. The objective of this study was to re-conduct
meta-analysis with meta-regression on the relationship
between HPV infection and the risk of breast cancer.
Results and discussion
Figure 1 depicts the process of selecting articles for the
final analysis through a data search. Based on the 3 SRs
to identify the association between HPV and the preva-
lence and odds ratio (OR) of breast cancer, a list was
compiled containing 85 references and 8122 cited and
related articles from PubMed and Scopus. We sequen-
tially applied the selection criteria into the total 8207 pa-
pers, and excluded (1) 8113 articles with a different
hypothesis, (2) 21 articles that were expert reviews or
systematic reviews, (3) 45 articles using case only stud-
ies, (4) 2 articles that were case-control studies without
HPV DNA-positivity in both groups [16,17], and (5) 2
articles published using duplicate samples [18,19]. The
older publication in 2005 by Tsai et al. [18] was excluded
because the samples used were the same as a publication
in 2007 [20] by the same group. In addition, the studies
published in 2009 by Lawson et al. [19] and Hang et al.
[21] used the same DNA specimens as each other; of
these, Lawson et al. [19] was excluded based on the suit-
ability of the hypothesis for our study.
Following the aforementioned exclusion process, 24
publications were selected for the meta-analysis [10,14,
20–41]. Table 1 summarizes the numbers of HPV DNA-
positive and HPV DNA-negative individuals in the case
and control group in these 24 case-control studies, orga-
nized according to the nationality of the study subjects,
types of DNA specimen, and 3 HPV subtypes. Of these
studies, He et al. [28] and Fu et al. [40] used the same
DNA specimens. Therefore, Fu et al. study published in
2015 [40] was used for the overall analysis, and He et al.
study published in 2009 [28] was used only for analyzing
the HPV 16 results. For similar reasons, data from
Glenn et al. published in 2012 [33] was used for the
Papers retrieved from the databases = 8,207
- lists from references of the systematic review = 85 
- lists fromcited or related articles by Pubmed = 8,122
Papers excluded = 8,179
- Different hypotheses = 8,113
- Review papers = 21
- Case-only studies = 45
Case-Control studies = 28
Papers excluded = 4 
- null results in both groups = 2
- duplicated samples = 2
The papers finally selected for this study = 24 
Fig. 1 Flow chart of article selection
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Table 1 Summary of the selected case-control studies by subtypes of human papillomavirus*
First author Year of publication Reference number Nation Tissue
type*
Any type 16 Subtype 18 Subtype 33 Subtype
Case (n/N) Control (n/N) Case (n/N) Control (n/N) Case (n/N) Control (n/N) Case (n/N) Control (n/N)
Yu 1999 22 China/Japan PET 18/52 1/20 18/52 1/20
Damin 2004 23 Brazil PET 25/101 0/41 14/101 0/41 10/101 0/41
de Villiers 2005 24 USA PET 25/29 20/29
Gumus 2006 25 Turkey FFT 37/50 16/50 20.37 9/16 35/37 14/16
Choi 2007 10 Korea PET 8/123 0/31
Tsai 2007 20 China FFT 8/62 2/32
Khan 2008 26 Japan PET 26/124 0/11 24/124 0/11 3/124 0/11 1/124 0/11
de Leon 2009 27 Mexico PET 15/51 0/43 10/51 0/43 3/51 0/43
Mendiazabauiz 2009 29 Mexico PET 3/67 0/40
Herrera-Goepfert 2011 41 Mexico PET 6/60 7/60 6/60 7/60
Mou 2011 30 China FFT 4/62 0/46 3/62 0/46 1/62 0/46
Chang 2012 31 China FFT 0/48 3/30
Frega 2012 32 Italy PET 9/31 0/12
Glenn 2012 33 Australia FFT 25/50 8/40 25/50 8/40
Sigaroodi 2012 34 Iran PET 15/58 1/41 4/79 0/51 4/79 0/51
Liang 2013 35 China FFT 48/224 6/37
Ali 2014 36 Iraq PET 60/129 3/44 33/129 0/44 35/129 1/44 16/129 1/44
Ahangar-Oskouee 2014 37 Iran PET 22/65 0/65 1/65 0/65
Manzouri 2014 38 Iran PET 10/55 7/51 2/55 0/51 1/55 0/51 1/55 0/51
Peng 2014 39 China FFT 2/100 0/50 2/100 0/50
Fu 2015 40 China PET 25/169 1/83
Li 2015 14 China PET 3/187 0/92
He 2009 28 China FFT 24/40 1/20
Heng 2009 21 Australia PET 1/26 0/17














overall and HPV 18 analyses, while the data from Heng
et al. published in 2009 [21] was used for analyzing
the HPV 16 results. Therefore, in the 22 publications
of case-control studies excluding the 2 articles that
used DNA specimens from the same hospital [21,28],
there were 1897 and 948 individuals in the case and
control group, respectively. When categorized by re-
gion, there were 10 articles in far-east Asia, 5 articles
in middle-east Asia, and 7 articles in other regions.
By specimen type, there were 15 articles using PET
and 7 articles using FFT. When the data was orga-
nized by HPV subtype, there were 11 articles on
HPV 16, 10 articles on HPV 18, and 5 articles on
HPV 33.
Regardless of HPV subtype, the risk of breast cancer was
4.02-fold higher (95 % CI: 2.42–6.68: I-squared =44.7 %) for
HPV DNA-positive individuals (Fig. 2). The Egger test
was used to determine publication bias, and the bias
coefficient was 0.91 which was not statistically sig-
nificant (p = 0.165) (Fig. 3).
Table 2 summarizes the results of subgroup analysis by
HPV subtype, region, and type of DNA specimen. Re-
sults by region showed that risk of breast cancer for
HPV DNA-positive individuals was 7.04-fold higher in
middle-east Asia (95 % CI: 2.43-20.42), 4.23-fold higher
in America regions (95 % CI: 1.06-16.84), and 2.60-fold
higher in far-east Asia (95 % CI: 1.25-5.38). By specimen
type, the risk was 5.60-fold higher for PET (95 % CI:
2.79-11.25) and 2.61-fold higher for FFT (95 % CI: 1.22-
5.61). Although there were differences in SOR by region,
specimen type and publication periods, all risks were
statistically significant. However, the CIs of SORs all
overlapped.
When we examined the results by HPV subtype, the
risk of breast cancer was, in descending order, 5.67-fold
higher for HPV 16 (95 % CI: 2.21-14.52), 3.64-fold
higher for HPV 33 (95 % CI: 1.26-10.48), and 2.97-fold
higher for HPV 18 (95 % CI: 1.64-5.38), and all risks
were statistically significant. Again, the CIs of SORs were
overlapping for 3 subtypes.
NOTE: Weights are from random effects analysis



























































































































Fig. 2 The forest plot of using a random‐effects summary estimates in 22 case‐control studies. ES : effect size; CI: confidence intervals
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The meta-regression analysis was performed on 26
datasets created around three subtypes, with nationality,
types of tissue, subtype, and publication year as the
variables. None of the variables showed statistical
significance (not shown).
In order to satisfy the criteria to prove that a specific
virus causes cancer [42], case-control studies must be
performed instead of case only studies [43]. However,
tumor-based case-control studies are susceptible to
measurement errors [44,45], and thus, systematic re-
views are needed to overcome this shortcoming.
According to the meta-analysis for results from 22
case-control studies, the risk of breast cancer due to
HPV infection was 4.02-fold higher. Even when the re-
sults were analyzed by categorizing into four regions,
two types of DNA specimen and two publication pe-
riods, the risk of breast cancer due to HPV was statisti-
cally significant. The findings provide supporting
evidence for the HPV infection as a risk factor of breast
cancer. Additionally, the CIs of SOR calculated in the
subgroup analysis were overlapping with one another,
and the results from meta-regression analysis showed
that none of the 4 variables caused heterogeneity. These
findings support the validity of the SOR calculated in
the meta-analysis.
The estimated SOR in this study was similar to previ-
ous meta-analysis results (Table 3). However, our meta-
analysis retrieved results from 22 case-control studies,
and therefore, has a narrower confidence interval be-
cause we were able to retrieve publications that were not
selected through electronic search. The list of 22 publi-
cations gathered in this manner will be important for re-
newal meta-analyses in the future.
Early study results were confusing, due to inappropri-
ate experimental design, small sample sizes, and unstan-
dardized HPV DNA detection methods [11,14,15].
However, Li et al. [12] commented that consistent study
results have been reported since 2006. Therefore, we
tried to conduct a subgroup analysis by dividing into be-
fore and after 2006, but because only 3 of the 21 publi-
cations were before 2006, we performed analysis with
2010 as the cut point. In terms of selecting region vari-
ables, 9 out of 16 studies selected in Zhou et al. [13] had
Asian subjects, whereas in this study it was 15 out of 22
studies that had Asian subjects. Thus, in the study, an
analysis was done after the 15 studies were separated
into 10 far-east and 5 middle-east Asia studies. Also,
Zhou et al. [13] reported the difference for each PCR
primer even if the CIs of SORs overlapped. In this study,
we used the subtype variable, in lieu of the variable of
PCR primer used. That is, we created 26 sets of database
after dividing HPV into 3 subtypes (16, 18, and 33) and
examined SOR by subtype. Not only the results showed
that the CIs of SOR calculated by subtype overlapped,
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Fig. 3 The funnel plot of using a mixed‐effects summary estimates in 22 articles (P‐value of Egger test =0.165). LogOR: log odds ratio; s.e.of
logOR: standard error of log odds ratio
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Table 3 Comparison of three meta-analyses for HPV infection and breast cancer risk
First author [reference number] Searching Periods Selected articles Total Cases Total Controls SOR (95 % CI)
Li [12] - May 2010 10 447 275 3.63 (1.42–9.27)
Simoes [11] - Jan 2011 9 448 279 5.9 (3.23–10.67)
Zhou [13] - Jun 2013 16 n.d. n.d. 3.24 (1.59–6.57)
This study - Sep 2015 22 1897 948 4.02 (2.42–6.68)
n.d not described
Table 2 Subgroup analyses by subtypes of human papillomavirus
Types Sub-group Numbers I-squared (%) SOR with 95 % CI by REM
Any 22 44.7 4.02 [2.42–6.68]
Nationality of subjects Far-East 10 16.4 2.60 [1.25–5.38]
Middle-East 5 66.4 7.04 [2.43–20.42]
America 5 59.2 4.23 [1.06–16.84]
Europe & Oceania 2 0.0 4.39 [1.77–10.86]
Specimen types PET 15 45.4 5.60 [2.79–11.25]
FFT 7 47.5 2.61 [1.22–5.61]
Year of publication −2010 9 0.0 5.10 [2.89–8.99]
2011- 13 60.1 3.55 [1.68–7.50]
16 11 32.5 5.67 [2.21–14.52]
Nationality of subjects Far-East 3 0.0 12.37 [2.83–54.15]
Middle-East 4 0.0 7.87 [1.76–35.23]
America 4 54.3 3.58 [0.61–21.03]
Specimen types PET 9 25.9 4.25 [1.57,11.54]
FFT 2 0.0 16.47 [2.94–92.18]
Year of publication −2010 5 0.0 12.47 [3.73–41.71]
2011- 6 30.1 3.25 [0.97–10.87]
18 10 0.0 2.97 [1.64–5.38]
Nationality of subjects Far-East 3 0.0 1.54 [0.26–9.20]
Middle-East 4 52.5 3.37 [0.70–16.22]
America 3 0.0 4.50 [1.89–10.68]
Specimen types PET 7 28.0 3.13 [1.09–9.03]
FFT 3 0.0 3.70 [1.54–8.88]
Year of publication −2010 4 12.4 1.59 [0.51–4.96]
2011- 6 0.0 4.62 [2.17–9.81]
33 5 0.0 3.64 [1.26–10.48]
Nationality of subjects Far-East 2 69.6 2.10 [0.06–68.51]
Middle-East 3 0.0 3.70 [0.98–13.90]
Specimen types PET 5 0.0 3.64 [1.26–10.48]
FFT - - -
Year of publication −2010 3 40.4 2.64 [0.44–15.76]
2011- 2 0.0 4.88 [0.87–27.56]
CIconfidence intervals, FFT fresh frozen tissue, PET paraffin-embedded tissue, REM random effect model
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Regarding the link between the Epstein-Barr virus in-
fection and breast cancer, it has been argued that differ-
ent kinds of control tissue cause heterogeneity [46]. Of
the 22 selected studies, we found that only 2 studies
used adjacent normal cells from the cancer tissue
[24,41], and the remaining 20 studies used normal breast
cells of non-cancer tissues. Therefore, an additional ana-
lysis by type of control tissue was not performed.
It has been proposed that not only HPV but also her-
pesvirus, polyomavirus, and beta retrovirus increase the
risk of breast cancer [47]. Proving these theories related
to viral infection is of great significance because it opens
up the possibility of using antiviral drugs to treat breast
cancer and vaccines to prevent breast cancer [8,48].
Conclusions
In conclusion, this meta-analysis supports the hypothesis
that HPV infection is a risk factor for breast cancer. In
near future, it is anticipated that nested case-control
studies will be actively performed, along with age-
matched case-control studies.
Methods
Search and selection of related articles
Since we were using 3 previously published systematic
reviews [11–13], we used the hand search method rather
than the electronic search method [49,50]. Publications
were found by searching the references of articles selected
in these 3 systematic reviews on the preferential basis.
And then lists of “cited articles” and “similar (related) arti-
cles” provided by the PubMed (www.ncbi.nlm.nih.gov/
pubmed) and Scopus (www.elsevier.com/solutions/sco-
pus) databases for each article were also considered for in-
clusion. This searching strategy assumes that studies
conducted with the ‘same research hypothesis’ have a high
possibility of being cited in related articles and that they
will have similar findings [51].
The final selection criteria were case-control studies
that detected HPV DNA in the tissue. Based on the titles
and abstracts for the papers in the compiled list, the fol-
lowing 5 exclusion criteria were applied sequentially. (1)
Articles with different hypothesis, (2) expert reviews or
systematic reviews, (3) case only studies, (4) case-control
studies without HPV DNA-positivity in both groups,
and (5) articles published by using the same DNA sam-
ples as another study. The remaining case-control stud-
ies after applying the 5 aforementioned criteria were
selected as publications for the final analysis.
Statistical analysis
Two researchers applied the exclusion criteria for each
publication and retrieved HPV-related data—the number
of HPV DNA-positive and HPV DNA-negative individ-
uals in the case and control group, nationality of study
subjects, types of DNA specimen, types of HPV sub-
types, and publication period. Using the obtained num-
ber of HPV DNA-positive and HPV DNA-negative
individuals in the case and control group, OR and 95 %
CI were calculated for each article. Based on the preva-
lence of HPV subtypes reported by the Zhou et al. [13],
data on high-risk type-specific HPV 16, 18, and 33 were
organized separately. Based on the nationality of study
subjects, groups were categorized into far-east Asia
(Korea, China, and Japan), middle-east Asia (Turkey,
Iran, and Iraq), America, and Europe & Oceania regions.
Specimen types were classified into PET and FFT groups.
Publication year was divided into 2 groups with 2010 as
the cut point.
The presence of heterogeneity in meta-analysis was
assessed using the I-squared value (%). The summary
odds ratio (SOR) for a random effect model and its 95 %
CI were calculated first because if the I-squared value is
0.0 %, using either a random effect model or a fixed ef-
fect model will result in the same value. To determine
the publication bias, Egger’s test for small-study effects
was conducted [52]. Additionally, a subgroup analysis
and a meta-regression analysis were conducted using the
4 potential variables thought to cause heterogeneity in
risks—geographic region, HPV DNA source, publication
year, and subtype of HPV. P-value of less than 5 % was
considered statistically significant, and STATA version
14 (www.stata.com) statistics program was used.
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